$PCVX (Vaxcyte, Inc.) — investor discussion on X

Vaxcyte $PCVX says VAX-31, its 31-valent pneumococcal vaccine, met all primary endpoints in pivotal adult Phase 3. It achieved noninferiority across all 32 serotype comparisons, with safety similar to PCV20/PCV21. OPUS-2/3 data due H1 2027. https://t.co/BAasUkKWVo

$PCVX VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20® (PCV20) and/or Capvaxive® (PCV21) Prespecified Co-Primary Immunogenicity Endpoints: In Adults 50 and Older, All 28 VAX-31 Serotypes Shared with PCV20 and/or PCV21 Met Noninferior

$PCVX Mizuhu this morning VAX-31 Adults Ph3 OPUS-1 Readout ==> Near Best-Case Scenario; Best-in-Class PCV Potential-Will be very difficult to refute that VAX-31 is showing best-in-class PCV potential here in this $8Bn+ &growing) market.

Vaxcyte rockets about 50% after its 31-strain pneumonia vaccine VAX-31 hit the main goals of a Phase 3 trial in adults 50 and older, matching Pfizer's Prevnar 20 and Merck's Capvaxive on shared strains and beating them on three unique ones. Analysts call it near best case. U.S. f

$PCVX Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate - Vaxcyte, Inc. https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-reports-positive-topline-d

All these stocks hit new 52 WEEK HIGHS at some point today NVIDIA $NVDA Taiwan Semiconductor $TSM CrowdStrike $CRWD Okta $OKTA Lumentum $LITE Warner Bros. Discovery $WBD Zeta Global $ZETA XP Inc $XP Petrobras $PBR.A Gerdau $GGB Vaxcyte $PCVX Genmab $GMAB Ultrapar $UGP Petrobras $